EGFR and carcinoma: Our findings revealed that these CD27+CD8+ T cells display a cytotoxic, exhausted, and tumor-reactive profile, closely matching the reported dysfunctional profile of the tumor-reactive immune repertoire (54, 55).This observation underscores their potential as a target for immunotherapy and suggests that EGFR-targeted re-activation of CD27 co-stimulatory signaling T cells may have a broad applicability across a diverse range of carcinomas (54, 55).